Summary
Vast amounts of information on medicines is available, especially online, but it is very hard to know what is reliable or even relevant for a specific patient. And, while each medicine comes with a detailed information leaflet, patients often find these difficult to read and understand.
This is an issue because when patients lack important information about their treatments, they may not take them correctly and this can result in further health problems. The OECD (Organisation for Economic Cooperation and Development) estimates that poor medication adherence may contribute to around 200 000 premature deaths in Europe every year.
The aim of Gravitate-Health is to develop a digital health information tool called the Gravitate Lens (G-Lens). As the name suggests, the G-Lens will focus (but not conceal or filter) approved information on medicines and guide patients to understandable, trustworthy, up-to-date information that meets the patient’s needs and fits with their health context and literacy levels. The functionality of the G-Lens will be supported by an open source digital platform.
More broadly, the project hopes to demonstrate that by making information on medicines more accessible and understandable, patients will be more likely to take their medicines correctly, resulting in better health outcomes and quality of life.
All stakeholders relevant to digital health information are involved in the project, including patient representatives, regulators, ministries, digital technology experts and more.
In addition to the open source platform underlying the G-Lens, the project will produce a white paper with recommendations on realistic strategies on the future use of digital services like electronic product information can be used to further minimise the risks associated with incorrect adherence to advice on medicines.
Achievements & News
April 2025
How can IHI and IMI projects harness the opportunities posed by real-world data and AI to make Europe a leader...
February 2025
IMI and IHI projects provide a neutral platform where public and private datasets can be shared within a secure environment...
June 2024
Both the PharmaLedger and Gravitate-Health projects are developing solutions that will make it easier and safer for patients to access...
February 2023
IMI projects are presenting results on remote clinical trials, patient information, health data, and real world evidence at the upcoming...
The GRAVITATE-Health project has devised a set of personas to guide its work on the G-Lens, a piece of open-source software which will help people zoom in to the information on a medicine that applies to them as individuals. ###
Personas are fictional but realistic descriptions of typical end-users of the product based on real-world data. After collecting the raw data from multiple sources, the project partners clustered the end-users based on recurring attributes, merging similar clusters and eliminating irrelevant ones. These segments represent the entire range of diversity represented in the raw data. The result was three end-user groups and six distinct personas: Maria, Filippo, Amalia, Pedro, Peter and Antonio.
From a smoker with IBS to a child with a feeding tube and the sibling of someone with Down’s Syndrome, we meet a diverse group of people whose circumstances represent those of a wide swathe of the population.
The GRAVITATE-Health personas are being used by the project partners to give everyone a common understanding of the end-users of the G-Lens. They are just the first instalment in a suite of user research tools that will be part of a continuous, iterative, living toolkit that will evolve as more data become available.
Find out more
- Read the article in full
Participants
Show participants on mapEFPIA companies
- Astrazeneca AB, Sodertaelje, Sweden
- Bayer Aktiengesellschaft, Leverkusen, Germany
- Eli Lilly And Company LTD, Basingstoke, United Kingdom
- F. Hoffmann-La Roche AG, Basel, Switzerland
- Grunenthal GMBH, Aachen, Germany
- Janssen Pharmaceutica Nv, Beerse, Belgium
- Mdsol Europe LTD, London, United Kingdom
- Mylan Ire Healthcare Limited, Dublin, Ireland
- Novartis Pharma AG, Basel, Switzerland
- Pfizer Limited, Sandwich, United Kingdom
- UCB Biopharma, Bruxelles / Brussel, Belgium
Universities, research organisations, public bodies, non-profit groups
- Agencia Espanola De Medicamentos Y Productos Sanitarios, Madrid, Spain
- Agentschap College Ter Beoordeling Van Geneesmiddelen, Utrecht, Netherlands
- Akershus Universitetssykehus Hf, Lorenskog, Norway
- Beth Israel Deaconess Medical Center, Inc Non Profit Corporation, Boston Ma, United States
- Echalliance Company Limited By Guarantee, Dublin, Ireland
- Hl7 International Fondation, Bruxelles / Brussel, Belgium
- Karolinska Institutet, Stockholm, Sweden
- Kobenhavns Universitet, Kobenhavn, Denmark
- Oslo Universitetssykehus Hf, Oslo, Norway
- Rijksinstituut Voor Volksgezondheid En Milieu, Bilthoven, Netherlands
- Servicio Madrileno De Salud, Madrid, Spain
- Spms - Servicos Partilhados Do Ministerio Da Saude Epe, Lisboa, Portugal
- Statens Legemiddelverk, Oslo, Norway
- The European Institute For Innovation Through Health Data, Oosterzele, Belgium
- Trinity College Dublin, Dublin, Ireland
- Universidad Politecnica De Madrid, Madrid, Spain
- Universita Cattolica Del Sacro Cuore, Milano, Italy
- Universitetet I Oslo, Oslo, Norway
- Universitetssykehuset Nord-Norge Hf, Tromso, Norway
- University College Dublin, National University Of Ireland, Dublin, Dublin, Ireland
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
- DLI - Dansk Laegemiddel Information A/S, Copenhagen, Denmark
- Datawizard SRL, Roma, Italy
- Empirica Gesellschaft Fur Kommunikations Und Technologieforschung Mbh, Bonn, Germany
- Felleskatalogen As, Oslo, Norway
- Guardtime Ou, Tallinn, Estonia
- Himss Europe GMBH, Berlin, Germany
- Lakemedelsindustriforeningens Service Aktiebolag, Stockholm, Sweden
- Mindview Symvouloi Epixeiriseon Kaierevnas Etaireia Periorismenis Efthynis, Athina, Greece
- Norsk E Helse As, Oslo, Norway
- Pharmaca Health Intelligence Oy, Helsinki, Finland
- Predictby Research And Consulting S.L., Barcelona, Spain
- The Synergist, Bruxelles / Brussel, Belgium
- Trifork Public As, Aarhus C, Denmark
Patient organisations
- Forum Des Patients Europeens, Brussels / Bruxelles, Belgium
Associated partners
- Datapharm Limited, Leatherhead Surrey, United Kingdom
Third parties
- Synergist Services, Bruxelles / Brussel, Belgium
Participants | |
---|---|
Name | EU funding in € |
Agencia Espanola De Medicamentos Y Productos Sanitarios | 70 000 |
Agentschap College Ter Beoordeling Van Geneesmiddelen | 197 375 |
Akershus Universitetssykehus Hf | 344 375 |
Datawizard SRL | 402 313 |
DLI - Dansk Laegemiddel Information A/S | 1 |
Echalliance Company Limited By Guarantee | 286 500 |
Empirica Gesellschaft Fur Kommunikations Und Technologieforschung Mbh | 534 554 |
Felleskatalogen As | 1 |
Forum Des Patients Europeens | 302 725 |
Frisq Holding AB (left the project) | 106 838 |
Guardtime Ou | 155 156 |
Himss Europe GMBH | 268 375 |
Hl7 International Fondation | 729 429 |
Karolinska Institutet | 429 966 |
Kobenhavns Universitet | 126 250 |
Lakemedelsindustriforeningens Service Aktiebolag | 1 |
Mindview Symvouloi Epixeiriseon Kaierevnas Etaireia Periorismenis Efthynis | 149 625 |
Norsk E Helse As | 296 250 |
Open Evidence (left the project) | 61 107 |
Oslo Universitetssykehus Hf | 155 000 |
Pharmaca Health Intelligence Oy | 1 |
Predictby Research And Consulting S.L. | 295 938 |
Servicio Madrileno De Salud | 128 752 |
Spms - Servicos Partilhados Do Ministerio Da Saude Epe | 141 000 |
Statens Legemiddelverk | 1 325 |
The European Institute For Innovation Through Health Data | 293 929 |
The Synergist | 91 813 |
Trifork Public As | 403 000 |
Trinity College Dublin | 336 491 |
Universidad Politecnica De Madrid | 609 554 |
Universita Cattolica Del Sacro Cuore | 151 813 |
Universitetet I Oslo | 1 883 734 |
Universitetssykehuset Nord-Norge Hf | 163 750 |
University College Dublin, National University Of Ireland, Dublin | 5 875 |
Third parties | |
Name | Funding in € |
Synergist Services | 157 188 |
Total Cost | 9 280 004 |